NEXT ADJUVANT

Features of our adjuvant

1The strongest parenteral immune response after intramuscular vaccination
  • The antigen was intramuscular injected to mice two times in two weeks intervals in the presence of various adjuvant.
  • The immune response was monitored by the level of IgG in serum.
  • The adjuvant shows the superiority than others.
Three mice per group were injected with 100ug OVA only (column 2), width 100 ug of alum (column 3), 10 ug of CpG (column 4), 50 ug of poly IC (column 5), 5 ug (column 6), or 10ug of Next adjuvant (column 7) twice for 4 weeks. The serum level of lgG was analyzed using ELISA in duplication.
2The strongest mucosal immune response after intranasal vaccination
  • The antigen was intranasally delivered to mice two times in two weeks intervals in the presence of various adjuvant.
  • The immune response was monitored by the level of IgG in serum and IgA in tear, nasal, and fecal.
  • The adjuvant shows the superiority than others.
Three mice per group were treated intranasally with 100ug OVA only (column 2), width 1 ug of alum (column 3), 10 ug of CpG (column 4), 10 ug of poly IC (column 5), 10 ug of monophosphoryl lipid A (column 6), or 10ug of Next adjuvant (column 7) twice for 4 weeks. The serum level of lgG was analyzed using ELISA in duplication.
Three mice per group were treated intranasally with 100ug OVA only (column 2), width 1 ug of alum (column 3), 10 ug of CpG (column 4), 10 ug of poly IC (column 5), 10 ug of monophosphoryl lipid A (column 6), or 10ug of Next adjuvant (column 7) twice for 4 weeks. The serum level of lgA in the tear (1st graph), nasal (2nd graph), and fecal (3rd graph) was analyzed using ELISA in duplication.
3Elicited a strong innate immune response in tumor model

Elicitation of the strong innate immune response by the adjuvant

4Elicited a strong nasal immune response in mouse influenza model

The novel adjuvant potentiates a nasal influenza vaccine

  • Female Balb/c mice (7 wk-old), 5 mice per group
  • Flu Vac : inactivated mouse-adapted PR8 (A/H1N1)
  • Vaccination by a single nasal drop
  • Vaccination : 0.5 ㎍ Flu Vac + 5 ㎍ adjuvant/ 0.5 ㎍ Flu Vac + 5 ㎍ poly(I:C)
  • Virus challenge (IN) : 100MLD50 mouse-adapted PR8 at 3 weeks after vaccination
5Ready to uptake by immune cells
  • The mouse blood cells can be stimulated and differentiated by the co-incubation of the adjuvant both in vivo and vitro.
  • No additional treatment is required for the delivery.
6High solubility
  • Up to 100 mg/ml solubility in DW or PBS
7Defined mode of action
  • The action of mode is fully understood.
8A short half-life in vivo
  • Less than 20 minutes for half-life. Labile and easily removable after the required effect is exhausted.
Short half-life in vivo, Easy for the assay of pharmacokinetics

Methos ; 5 ml of 100% calf serum was mixed with 1 ml of adjuvant (1 mg/ml) and incubated for the indicated time at 37℃.
At each time point, total amount of the adjuvant was determined by a proprietary method.
9An easy pharmacokinetics assay
  • The assay for the pharmacokinetics of the adjuvant is well established.
  • More than 200 samples can be analyzed in a single day.
10A long shelf-life
  • More than two years at ambient temperature in PBS
  • Can lypophlized without lost the efficacy
Long shelf life

Methos ; the adjuvant in PBS (2 mg/ml) and incubated for the indicated time at 45℃.
At each time point, total amount of the adjuvant was determined by a proprietary method.
11Can be mixed with any antigens in a single step without any special equipment Steps for the mixing with antigen
  • Take antigen in PBS
  • Add the pre-determined amount of the adjuvant
  • Invert mix for 2 minutes and aliquot
12High recoverability of antigen
  • To determine the stability of the antigen in vaccine, the antigen should be recovered from the adjuvant mixture with a high efficacy.
  • The antigen can be recovered from the adjuvant in 100% by a single step.
Procedure to determine the recoverability of the antigen from the adjuvant mixture

1. Take the vaccine mixture of antigen and adjuvant
2. Take the mixture and load to a SDS-PAGE gel without any additional step of processing
13Economical
  • The production cost of the adjuvant is the lowest considering the efficacy and versatility of the vaccine.
14An established mass production system
  • A month for the production of 100,000 dose
  • The current system can be further extended up to the 1 million dose per month.
15Safety
  • ED50 of mouse by SC injection is about 2.5-5 ug.
  • LD50 of mouse by SC injection and Nasal droplet is about 100 ug.

Toxic after a multiple injection

1. Total 7 C57black6 mice was injected with 5 ug of the adjuvant in final 50 ul in PBS by SC in every week for 4 weeks.
2. In each injection day, the survival of mice was monitored.
16Homogeneous manufacture and stringent QC
  • The adjuvant is a single peak in HPLC analysis.
  • The QC system for the consistent production has been estabilished.